Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 138

Sort by

Sort Order Select

Journal Articles

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

Chung Hoow Kok, PhD BSc, Liu Liu, PhD BSc, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Verity A Saunders, Phuong Dang, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 663.

https://doi.org/10.1182/blood-2019-125446

Published: 2019

Journal Articles

Hematopoietic Cell Cluster Identifier (HCCI): A Knowledgebase Computational Tool to Facilitate the Characterization of Hematopoietic Cell Populations in Single Cell RNA-Sequencing

Gaurav Kumar, PhD, Adam Ertel, PhD, Nicole Naranjo, MS, Shuvanon Shahid, BS, Lucia Languino, PhD, Paolo Fortina, MD PhD

Blood (2019) 134 (Supplement_1): 3587.

https://doi.org/10.1182/blood-2019-127175

Published: 2019

Journal Articles

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Shaun Fleming, MBBS,, Cheng-Hong Tsai, MD MSc, Hartmut Döhner, MD, Konstanze Döhner, Elli Papaemmanuil, PhD, Hwei-Fang Tien, MD, PhD, John Reynolds, PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Hsin-An Hou

Blood (2019) 134 (Supplement_1): 1392.

https://doi.org/10.1182/blood-2019-128243

Published: 2019

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Rajshekar Chakraborty, MD, Lisa Rybicki, MS, Megan Nakashima, MD, Robert M. Dean, MD, Beth M. Faiman, PhDCNP, Christy J. Samaras, DO, Nathaniel Rosko, PharmD, Jason Valent, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 4359.

https://doi.org/10.1182/blood-2019-123861

Published: 2019

Journal Articles

Clinical Outcomes of Multiple Myeloma Patients Treated with Direct Oral Anticoagulants for Immunomodulatory Drug Associated Venous Thromboembolism

Zachary Crowther, Jamie Doyle, Stanford Taylor, Nadia Ali, MD

Blood (2019) 134 (Supplement_1): 4964.

https://doi.org/10.1182/blood-2019-131396

Published: 2019

Journal Articles

Machine Learning Approach Identifies Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS)

Uta Oelschlaegel, PhD, Kevin Blighe, PhD, Susann Winter, PhD, Katja Sockel, MD, Martin Bornhäuser, MD, Shahram Kordasti, MD PhD, Uwe Platzbecker

Blood (2019) 134 (Supplement_1): 4251.

https://doi.org/10.1182/blood-2019-128042

Published: 2019

Journal Articles

The Splicing Factor RBM17 Supports Leukemia Stem Cell Self-Renewal

Lina Liu, Ana Vujovic, Joshua Xu, Kristin Hope, PhD, Yu Lu, PhD

Blood (2019) 134 (Supplement_1): 1238.

https://doi.org/10.1182/blood-2019-126287

Published: 2019

Journal Articles

Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia

Ibrahim Aldoss, MD, Dongyun Yang, PhD, Raju Pillai, MD, James F Sanchez, PhD, Ahmed Aribi, MD, Haris Ali, MD, Karamjeet S Sandhu, MD, Monzr Al Malki, MD, Matthew Mei, MD, Amandeep Salhotra, MD, Samer K. Khaled, MD, Ryotaro Nakamura, MD, Weili Sun, MD PhD, Margaret R O'Donnell, MD, David S Snyder, MD, Anthony S. Stein, MD, Stephen J Forman, Guido Marcucci, Vinod A. Pullarkat, MD

Blood (2018) 132 (Supplement 1): 334.

https://doi.org/10.1182/blood-2018-99-113670

Published: 2018

Journal Articles

The Prognostic Value of TP53 Mutations Depends on Clinical Backgrounds in Pediatric Patients with Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2018-99-115617

Published: 2018

Journal Articles

Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal

Margaret L. MacMillan, MD, Shernan G. Holtan, MD, Armin Rashidi, MD PhD, Todd E. DeFor, MS, Claudio G Brunstein, MD PhD, John E. Wagner, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD

Blood (2018) 132 (Supplement 1): 67.

https://doi.org/10.1182/blood-2018-99-113085

Published: 2018

Journal Articles

A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL

Blood (2018) 132 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2018-99-112162

Published: 2018

Journal Articles

Epigenetic Modifier Mutations in the LL-100 Panel

Hilmar Quentmeier, PhD, Claudia Pommerenke, PhD, Hans G. Drexler, MD PhD

Blood (2018) 132 (Supplement 1): 5271.

https://doi.org/10.1182/blood-2018-99-110060

Published: 2018

Journal Articles

Developing Applicable and Cost-Efficient Screens for Early Detection of AML

Sagi Abelson, Stanley W.K. Ng, Ting Ting Wang, Scott V. Bratman, John E. Dick

Blood (2018) 132 (Supplement 1): 90.

https://doi.org/10.1182/blood-2018-99-113403

Published: 2018

Journal Articles

Prediction of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm

Yasuyuki Arai, MDPhD, Tadakazu Kondo, MD PhD, Kyoko Fuse, MD, Yasuhiko Shibasaki, MD, Masayoshi Masuko, MD PhD, Junichi Sugita, Takanori Teshima, Naoyuki Uchida, MD PhD, Takahiro Fukuda, Kazuteru Ohashi, MD PhD, Yukiyasu Ozawa, MD PhD, Tatsuo Ichinohe, MD PhD, Yoshinobu Kanda, MD PhD, Yoshiko Atsuta, MD PhD

Blood (2018) 132 (Supplement 1): 68.

https://doi.org/10.1182/blood-2018-99-114794

Published: 2018

Journal Articles

Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient

Afshin Beheshti, PhD, Kristen E. Stevenson, MS, Ravi Dashnamoorthy, PhD, Charles Vanderburg, PhD, David M Weinstock, MD, Andrew M. Evens, DO, MSc

Blood (2018) 132 (Supplement 1): 2973.

https://doi.org/10.1182/blood-2018-99-116789

Published: 2018

Journal Articles

The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Blood (2018) 132 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2018-99-114168

Published: 2018

Journal Articles

Early Prediction of Stable MR 4.5 By Achievement of 2.8 Log Reduction in BCR-ABL1 qPCR Levels at 6 Months in Patients with Chronic Myeloid Leukemia Treated with Frontline Imatinib

Aisling Nee, MB, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD

Blood (2018) 132 (Supplement 1): 3022.

https://doi.org/10.1182/blood-2018-99-110135

Published: 2018

Journal Articles

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not

Warren Fingrut, BSc, MD, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD

Blood (2018) 132 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2018-99-113938

Published: 2018

Journal Articles

Implication of the Long Non-Coding RNA Crnde in Multiple Myeloma

Antoine David, MS, Ashley Ohnona, Alexis Talbot, MD, Wendy Cuccuini, Jean-Paul Fermand, MD, Jean Soulier, MDPhD, Bertrand Arnulf, MD PhD, Jean Christophe Bories, PhD, Michele Goodhardt, PhD, David Garrick, PhD

Blood (2017) 130 (Supplement 1): 4357.

https://doi.org/10.1182/blood.V130.Suppl_1.4357.4357

Published: 2017

NARROW

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

Hematopoietic Cell Cluster Identifier (HCCI): A Knowledgebase Computational Tool to Facilitate the Characterization of Hematopoietic Cell Populations in Single Cell RNA-Sequencing

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Clinical Outcomes of Multiple Myeloma Patients Treated with Direct Oral Anticoagulants for Immunomodulatory Drug Associated Venous Thromboembolism

Machine Learning Approach Identifies Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS)

The Splicing Factor RBM17 Supports Leukemia Stem Cell Self-Renewal

Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia

The Prognostic Value of TP53 Mutations Depends on Clinical Backgrounds in Pediatric Patients with Acute Lymphoblastic Leukemia

Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal

A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL

Epigenetic Modifier Mutations in the LL-100 Panel

Developing Applicable and Cost-Efficient Screens for Early Detection of AML

Prediction of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm

Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient

The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Early Prediction of Stable MR 4.5 By Achievement of 2.8 Log Reduction in BCR-ABL1 qPCR Levels at 6 Months in Patients with Chronic Myeloid Leukemia Treated with Frontline Imatinib

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not

Implication of the Long Non-Coding RNA Crnde in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only